CLOs on the Move

Novo Nordisk Canada

www.novonordisk.ca

 
Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 employees in 77 countries, and markets its products in more than 165 countries.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Rx Systems

Rx Systems is a Saint Charles, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rafael Pharmaceuticals

We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer.

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

EDAP TMS

EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.